A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

← catalyst calendar

NCT02779751

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With Merck Sharp & Dohme LLC.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

100estimated

Sites

Countries

Belgium, France, Italy +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2016-11-14

actual

When the study began enrolling

Primary completion

2020-02-03

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2026

estimated

The whole study's end, after follow-up

First posted

2016-05-20

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-01-26

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non Small Cell Lung Cancer
Breast Cancer

Interventions

Drug: Abemaciclib — also filed as LY2835219
Drug: Pembrolizumab
Drug: Anastrozole

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with One or More Serious Adverse Event(s) (SAEs)

measured Baseline through Study Treatment Completion (Approximately 6 Months)

Number of Participants with Non-Serious Adverse Event(s)

measured Baseline through Study Treatment Completion (Approximately 6 Months)

Publications

PMID 34746886 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed